recurr chromosom gain on most common featur human hepatocellular carcinoma hcc gain contribut hepatocarcinogenesi still unclear identifi target gene precis determin shortest region overlap sro breakpoint necessari similarli role loss major cytogenet aberr hcc need determin fifti hcc examin aid microsatellit marker distribut both arm chromosom detect allel gain effect cutoff valu allel imbal index set 0.70 allel show imbal subject multiplex pcr us retain allel intern control determin whether imbal result chromosom gain loss sro gain defin d1s2878-d1s2619 1q23.-q25.3 16.9 involv case gain number copi certain oncogen region seem critic pathogenesi hcc contrast centromer breakpoint gain vari tend occur mainli pericentromer region case rearrang specif gene associ gain unlik hand sro delet defin d1s2893-d1s450 1p36.32-p36.22 5.1 four known put tumor-suppressor gene tp73 riz1 nbl1/dan cdkn2c outsid sro suggest presenc candid gene critic role hepatocarcinogenesi
data clinic trail shown antitumor effect onyx-015 e1b 55kda-defici adenoviru monotherapi insuffici enhanc effici cnhk200-me anoth e1b 55kda-defici adenoviru arm mous endostatin gene construct antitumor activ hepatocellular carcinoma hcc vitro vivo investig select replic cytotox cnhk200-me hep3b hepgii cell independ p53 statu confirm via tcid50 5dimetylthiazol 5-diphenyltetrazolium bromid mtt assai potent tumor growth suppress smmc-7721 xenograft nude mice observ synergist effect carrier viru therapeut gene suggest moreov comparison nonrepl adenoviru carri same therapeut gene amplifi transgen express mous endostatin vitro vivo confirm western blot elisa assai effect angiogenesi inhibit replic cnhk200-me nude mice xenograft demonstr immunohistochemistri conclus recombin adenoviru cnhk200-me replic-compet oncolyt viru mediat high express therapeut gene becaus cnhk200-me capabl replic lyse hcc cell select effect tumor growth suppress antiangiogen activ hcc xenograft nude mice hold good potenti treatment hcc
de-gamma-carboxyprothrombin dcp known protein induc vitamin absenc antagonist abnorm prothrombin level serum dcp us clinic diagnosi prognosi patient hepatocellular carcinoma hcc previou immunohistochem studi show dcp express cancer tissu surround non-cancer tissu hcc patient howev clinic signific dcp express non-cancer tissu hcc patient remain unclear studi examin relationship histochem express dcp cancer non-cancer tissu clinic outcom hcc patient retrospect studi perform 132 patient singl primari hcc nodul express dcp tissu evalu immunohistochem stain us anti-dcp antibodi mu-3 serum dcp level determin us enzym immunoassai doubl antibodi sandwich system experiment clinic data process univari multivari statist analys dcp express observ non-cancer tissu relat poorer prognosi univari multivari analys show dcp express cancer non-cancer tissu signific prognost factor furthermor combin evalu tissu dcp express serum dcp level show prognosi poorest patient show posit tissu dcp express high level serum dcp result suggest immunohistochem evalu dcp express cancer non-cancer tissu serv valuabl factor prognosi hcc patient combin evalu tissu dcp express serum dcp level will valuabl factor alon effect treatment prognosi
54-year-old male hepatocellular carcinoma hcc underw transcathet arteri embol tae nearbi hospit refer hospit purpos addit treatment hcc becaus tae complet therapi hcc grow protrud left lobe liver laparoscop radio-frequenc ablat rfa chosen treatment hcc insert laparoscop abdomin caviti observ hcc unexpectedli adher mesenteri result tae perform previous cut adher mesenteri remov tumor combin therapi percutan ethanol inject rfa pei-rfa develop depart perform tumor tumor successfulli abrog pei-rfa suffici safeti margin confirm comput tomographi treatment
examin feasibl liver-direct vivo gene therapi administ recombin adenovirus carri report lacz gene retrograd common bile duct rat well antegrad portal vein transduct effici lacz gene liver estim histochem x-gal stain quantit chemiluminesc report gene assai retrograd infus adenovirus common bile duct shown successfulli induc transgen express liver transduct effici induc intrabiliari adenovir administr significantli differ induc intraport adenovir administr transgen express induc intraport intrabiliari adenovir administr observ predominantli periport area consider number cell express transgen detect lobular centrilobular area mild infiltr inflammatori cell liver mild hyperplast chang hepatocyt observ intrabiliari intraport adenovir administr howev hepat damag estim patholog substanti furthermor intrabiliari intraport adenovir administr result mild elev liver-relat serum biochem paramet appar complic observ rat result demonstr present studi suggest retrograd administr adenovirus common bile duct induc effici transgen express liver caus sever advers effect support feasibl adenoviru-mediat gene transfer liver clinic set mean endoscop retrograd cholangiographi
classifi hepatocellular carcinoma hcc base find digit subtract imag dsi compar dsi diagnost imag modal assess reliabl dsi perform patient hcc nodul enhanc pattern blood flow tumor assess earli phase portal phase late phase addit find obtain dsi compar obtain helic digit subtract angiographi dsa co2 angiographi arteri portographi ctap nodul blood flow detect 88.9 earli-phase dsi 84.7 helic 86.1 dsa 93.1 co2 angiographi earli-phase dsi demonstr hypervascular enhanc hcc nodul 16.7 includ nodul diagnost imag modal fail identifi tumor blood vessel nodul locat deep region 87.5 bodi surfac regard nodul 10.4 tumor vessel visual earli phase late-phase dsi demonstr rel poor enhanc compar normal hepat parenchyma late-phase defect tumor enhanc observ nodul 95.8 dsi demonstr characterist find hcc enhanc earli phase portal phase late phase permit classif hcc perform
sodium butyr short-chain fatti acid produc ferment gastrointestin tract induc differenti sever kind cancer inhibit histon deacetylas activ report butyr stimul hepatocellular carcinoma cell normal phenotyp sodium butyr affect both differenti apoptosi investig express bcl-2-relat gene human hepatocellular carcinoma cell line hcc-t express anti-apoptot bcl-2 mcl-1/eat up-regul treatment pro-apoptot bax express chang gene express earli stage butyr-stimul investig differenti displai assai cdna express arrai laminin keratin increas stimul sodium butyr result cdna express arrai reveal up-regul cell cycl inhibitori gene cyclin-depend kinas inhibitor interferon-relat gene stat2 down-regul cyclin-depend kinas cyclin up-regul product p21waf-1 mcl-1/eat confirm western blot cytoskelet chang indic up-regul laminin keratin import factor decreas malign phenotyp cancer cell up-regul interferon-relat gene indic butyr-treatment induc similar phenotyp chang induc type interferon studi suggest sever target gene futur gene therapi cancer gene prevent cancer develop pre-malign tissu
purpos bm-387032 novel cyclin-depend kinas inhibitor current phase clinic trial anticanc therapi oral bioavail bm-387032 found rat absorpt first-pass metabol evalu possibl reason incomplet oral bioavail rat method male spragu-dawlei rat given singl dose bm-387032 intraarteri 9.1 mg/kg oral 9.1 mg/kg intraport mg/kg rout excret bm-387032 intraven dose investig bile-duct-cannul rat rate metabol bm-387032 investig liver microsom permeabl bm-387032 evalu us caco-2 cell vitro model intestin epithelium determin bm-387032 p-glycoprotein substrat brain uptak studi conduct p-glycoprotein knockout versu wildtyp mice result exposur rat intraport dose similar intraarteri dose indic absorpt plai greater role liver first-pass metabol low oral bioavail rat intraven dose percent dose excret unchang urin bile 9-h period respect vitro studi rat liver microsom show low rate metabol bm-387032 caco-2 cell permeabl bm-387032 &lt nm/s apic basolater direct 161 nm/s basolater apic direct indic substrat intestin efflux transport p-glycoprotein bind assai show bm-387032 p-glycoprotein modul brain penetr studi mice show brain level bm-387032 3.5-fold higher p-glycoprotein knockout mice wildtyp mice provid evid bm-387032 p-glycoprotein substrat conclus poor absorpt plai greater role extens first-pass metabol incomplet oral bioavail bm-387032 rat efflux transport p-glycoprotein respons limit absorpt bm-387032 appear substrat p-glycoprotein
purpos shown previous carbogen breath rodent increas uptak anticanc drug tumour aim studi extend observ rodent model us anticanc drug 5-fluorouracil 5fu 5fu pharmacokinet tumour plasma physiolog effect tumour carbogen investig determin locu carbogen action augment tumour uptak 5fu method two differ tumour model us rat gh3 prolactinoma xenograft s.c nude mice rat h9618a hepatoma grown s.c syngen buffalo rat uptak metabol 5fu both tumour model host carbogen breath studi non-invas us fluorin-19 magnet reson spectroscopi f-mr plasma sampl buffalo rat us construct nonmem pharmacokinet model physiolog effect carbogen tumour studi us p-mr energi statu ntp/pi gradient-recal echo magnet reson imag gre-mri blood flow oxygen result both tumour model carbogan-induc gre-mri signal intens increas approxim consist increas tumour blood oxygen flow gh3 xenograft f-mr show carbogen signific effect 5fu uptak metabol tumour p-mr show chang ntp/pi ratio h9618a hepatoma f-mr show carbogen effect tumour 5fu uptak significantli 0.0003 increas 5fu elimin tumour i.e decreas 1/2 significantli 0.029 increas rate metabol cytotox fluoronucleotid fnuct pharmacokinet analysi show carbogen increas rate tumour uptak 5fu plasma increas rate remov p-mr show signific p&lt 0.02 increas hepatoma ntp/pi ratio transmembran gradient 0.11 unit conclus suggest carbogen transient increas tumour blood flow effect alon increas uptak anticanc drug secondari mechan oper case hepatoma increas tumour energi statu gradient suffici augment 5fu metabol cytotox fnuct gh3 xenograft case carbogen breath doe univers lead increas uptak anticanc drug
cd-1 mice commonli us oncolog metabol toxic support drug discoveri develop examin drug metabol toxic properti chemic entiti hand athym nude mice prefer anim investig tumor growth inhibit frequent ask question metabol pharmacokinet characterist xenobiot two mous strain compar address issu character drug metabol efflux transport properti both strain differ organ metabol stabil set compound metabolit format cytochrom p450 cyp marker substrat testosteron ethoxyresorufin pentoxyresorufin measur liver microsom drug conjug studi disappear 7-hydroxycoumarin format glucuronid sulfat conjug freshli prepar liver slice addit mrna express level main cyp gene drug efflux transport investig real-time rt-pcr liver kidnei intestin adren gland signific differ enzymat activ metabolit format observ two strain mrna express profil cyp drug transport gene similar cd-1 nude mice
two case hepatoblastoma uniqu karyotyp chang describ on case 2-year-old boi unbalanc chromosom transloc involv 4q35 sole chromosom abnorm clonal karyotyp tumor add q35 [3]/46 xy[9] case 2-year-old boi karyotyp analys reveal clonal karyotyp +del p22 +del p12 +18 +19 +20 +22[4]/46 xy[12] review two case togeth previou report underscor signific numer structur chromosom abnorm develop hepatoblastoma present result show imbal termin region sole chromosom abnorm hepatoblastoma found imbal chromosom region chromosom contribut develop hepatoblastoma
unev pregnanc boi born vacuum extract 40.6 week' gestat physic examin reveal sever malform due partial trisomi [karyotyp dup p13p24 three month birth boi present hepatoblastoma distant metastas treat chemotherapi combin surgeri follow-up year resect hepatoblastoma still complet remiss knowledg first case report patient constitut partial trisomi associ hepatoblastoma
oxid stress carcinogen metabol seem particip liver tumor product rat n-diethylnitrosamin import carcinogen us liver cancer anim model indirect alkyl agent produc dna-ethyl adduct oxid stress contrast n-ethyl-n-nitrosourea direct mutagen gener dna-ethyl adduct doe produc liver tumor rat given under oxid stress condit partial hepatectomi phenobarbit treatment gain insight relat oxid stress hepatocarcinogen induct preneoplast liver lesion compar among three differ initi protocol relat initi-promot-resist hepatocyt model addit liver lipid peroxid level determin thiobaritur acid reactiv substanc studi earli initi stage rat initi n-ethyl-n-nitrosourea dai treatment develop fewer smaller gamma-glutamyl transpeptidas posit preneoplast lesion rat initi n-diethylnitrosamin pre-treatment antioxid quercetin befor n-diethylnitrosamin initi significantli prevent develop gamma-glutamyl transpeptidas-posit lesion increas lipid peroxid level induc n-diethylnitrosamin initi n-ethyl-n-nitrosourea induc increment importantli pre-treatment quercetin decreas lipid peroxid induc n-diethylnitrosamin result show correl lipid peroxid hepatocarcinogen support import role oxid stress liver carcinogenesi
hepatocellular carcinoma usual preced chronic inflamm howev molecular mechan hepatocarcinogenesi well known recent report mitochondri dysfunct plai import role hepatocarcinogenesi via product free radic furthermor prove l-carnitin effect protect mitochondri function vivo investig whether long-term administr l-carnitin prevent hepat subsequ hepatocellular carcinoma long-evan cinnamon rat analyz model hepatocarcinogenesi result indic oxid stress elicit abnorm accumul copper increas amount free fatti acid therebi induc mitochondri dysfunct result cell death enhanc secondari gener reactiv oxygen speci significantli inhibit carnitin treatment final occurr placent glutathion s-transferas-posit foci marker preneoplast lesion hepatocarcinogenesi significantli inhibit l-carnitin fact suggest mitochondri injuri plai essenti role develop hepatocarcinogenesi clinic us carnitin excel therapeut potenti individu chronic hepat
object search clinic applic melittin mel treat hepatocellular carcinoma mel gene method recombin adenovirus carri mel gene alpha-fetoprotein afp promot ad-rafp-mel construct through bacteri homolog recombin system effici adenoviru-mediat gene transfer inhibitori effect ad-rafp-mel prolifer hepatocarcinoma cell determin x-gal stain mtt assai respect tumorigen hepatocarcinoma cell transfect ad-rafp-mel antitumor effect ad-rafp-mel transplant tumor nude mice detect vivo result mel mrna transcrib bel-7402 hepatocellular carcinoma cell transduct ad-rafp-mel effici adenoviru-mediat gene transfer bel-7402 cell 100 multipl infect ad-rafp-mel vitro high vivo inhibit rate ad-rafp-mel ad-rafp bel7402 cell 66.2 +/- 2.7 2.9 +/- 2.3 30.83 6.6 mtt assai inhibit rate ad-cmv-mel bel7402 smmc7721 l02 cell 58.9 +/- 9.6 65.9 +/- 3.8 31.7 +/- 1.2 respect ad-rafp-mel 66.2 +/- 2.7 16.1 +/- 6.6 7.5 +/- 3.3 respect 1.27 0.27 11.31 3.5 12.12 2.7 versu ad-cmv-mel group same cell tumorigen rate hepatocarcinoma cell transfect ad-rafp-mel decreas signific antineoplast effect detect transplant tumor nude mice intratumor inject ad-rafp-mel conclus ad-rafp-mel inhibit specif prolifer afp-produc human hepatocarcinoma cell vitro vivo suggest anim toxin gene us antitumor gene
hepatocyt growth factor plai multipl role cancer act motil invas stimul factor promot metastasi tumour growth furthermor act power angiogen factor pivot role factor cancer indic hgf potenti target cancer therapi past few year rapid progress develop tool target hgf context cancer therapi includ develop antagonist small compound antibodi genet approach current articl discuss potenti valu hgf receptor target cancer therapi current develop anti-hgf research clinic valu hgf prognosi treatment
object hepatocellular carcinoma hcc on most preval malign china due limit efficaci current avail therapi respons larg number death ifn-alpha therapi shown promis treatment variou form human cancer consid treatment hcc previou result group show high dose ifn-alpha exert signific antiprolif effect mhcc97 human xenograft nude mice mhcc97 cell test vitro here present experi design character molecular mechan underli defect respons mhcc97 cell ifn-alpha elucid mechan underli defect respons mhcc97 ifn-alpha help explain possibl overcom clinic failur form tumor therapi method ifn-alpha administ 000 000 iu/ml rang strongli inhibit prolifer cell line gene express profil mhcc97 cell obtain befor treatment ifn-alpha us cdna microarrai analysi transcript activ relev gene respond ifn-alpha cdna microarrai experi confirm rt-pcr northern blot analysi transient transfect express vector us restor p48-isgfgamma irf9 protein level cell prolifer evalu us mtt assai result ifn-alpha treatment caus activ sever signal transduct pathwai mhcc97 cell lack antiprolif effect found mainli deriv defect activ transcript factor isgf3 requir jak/stat signal show defect isgf3 activ mainli caus absenc on essenti compon protein p48-isgfgamma mhcc97 cell inde transient express p48-isgfgamma restor sensit ifn-alpha mrna level p48-isgfgamma normal mhcc97 cell mutat detect gene code protein hypothes mutat alter messag protein stabil lead reduc protein level observ conclus result confirm import role jak/stat signal antiprolif effect ifn-alpha tumor cell indic defect isgf3 caus resist ifn-alpha treatment
hepat epithelioid hemangioendothelioma heh rare vascular tumor liver unpredict malign potenti growth lead hepat failur extrahepat metastasi death surgic resect liver transplant treatment choic metastasi identifi sever antineoplast agent propos case nonresect heh report case 52-year-old patient heh metastat lung successfulli treat oral thalidomid therapi
purpos establish stabl green fluoresc protein gfp -express metastat human hepatocellular carcinoma hcc cell line differ metastat potenti long-term vivo studi metastasi angiogenesi method pire2-egfp vector contain enhanc gfp gene transfect mhcc97-h mhcc97-l hcc cell line differ metastat potenti stabil gfp express basic biolog characterist invas abil vitro spontan metastasi vivo cell line mhcc97-hg mhcc97-lg studi microvessel densiti mvd orthotop implant tumor compar anti-cd31 immunohistochem stain real-time angiogenesi metastasi gfp-transfect tumor detect intravit fluoresc microscop result gfp-transfect cell line stabli express green fluoresc absenc g418 36-dai period compar parent cell line exhibit distinct differ biolog characterist mhcc97-hg show aggress invas spontan metastat behavior mhcc97-lg parent cell line mhcc97-h p&lt 0.01 mvd level induc mhcc97-hg orthotop implant tumor significantli higher mhcc97-lg p&lt 0.01 real-time angiogenesi sequenti step metastasi detect clearli under intravit fluoresc microscop conclus two stabl gfp-express hcc cell line same genet background differ metastat potenti establish us model monitor metastasi angiogenesi hcc
purpos screen hepatocellular carcinoma hcc conduct year conclus evid screen reduc hcc mortal aim studi assess effect screen hcc mortal peopl increas risk method studi includ 816 peopl ag 35-59 year hepat viru infect histori chronic hepat urban shanghai china particip randomli alloc screen 373 control 443 group control receiv screen continu us health-care facil screen group particip invit afp test ultrasonographi examin everi month screen stop decemb 1997 time screen group particip offer five ten time particip follow decemb 1998 primari outcom measur hcc mortal result screen group complet 58.2 percent screen offer screen group compar control group number hcc versu subclin hcc 60.5 versu small hcc 45.3 versu resect achiev 46.5 versu 7.5 5-year surviv rate 65.9 52.6 46.4 versu 31.2 7.2 respect thirti-two peopl di hcc screen group versu control group hcc mortal rate significantli lower screen group control 83.2/100 000 131.5/100 000 respect mortal rate ratio 0.63 0.41-0.98 conclus find indic biannual screen reduc hcc mortal
object evalu effect toxic oxaliplatin combin capecitabin xeloda second-line chemotherapi regimen patient advanc gastric cancer method twenti-four patient advanc gastric cancer treat multipl chemotherapi regimen present poor respons allot regimen oxaliplatin mg/m 2-hour infus d15 capecitabin 1250 mg/m divid two daili dose given d14 adopt cycl repeat everi dai patient receiv two cycl result patient evalu have receiv cycl chemotherapi total cycl overal respons rate 29.2 includ time tumor progress ttp month median month durat remiss month median month major toxic bone marrow suppress nausea/vomit conclus oxaliplatin combin capitabin effect secondari line regimen patient advanc gastric cancer protocol activ well toler clinic studi warrant
background imprint gene insulin-like growth factor igf2 h19 plai import role variou malign includ hepatocellular carcinoma hcc materi method us dna microarrai patient follow-up data examin relationship express igf2 h19 hcc result found imbal level igf2 h19 transcript correl advanc tumor stage poor outcom hcc patient conclus addit known epigenet genet abnorm malign find suggest alter transcript two imprint gene contribut progress hcc
hepat complic associ cholestasi occur frequent hematopoiet stem cell transplant recipi bile acid seem sensit indic cholestasi author monitor total serum bile acid level addit standard liver function test recipi allogen transplant june 1999 septemb 2000 observ suggest bile acid earli sensit marker hepat gvhd specif bilirubin cholestasi absenc hepat gvhd bile acid seem sensit bilirubin routin monitor bile acid hematopoiet stem cell transplant indic
primari cancer gallbladd unusu most case gallbladd cancer found advanc stage accompani invas liver metastas lymph node distant organ periton dissemin studi first examin effect mitogen-activ protein kinas kinas mek inhibitor product matrix metalloproteinas mmp urokinas-type plasminogen activ upa tissu inhibitor metalloproteinas timp human gallbladd cancer cell line noz cell vitro mek inhibitor pd98059 u0126 inhibit product mmp-2 mmp-9 high upa upregul timp timp-1 timp-2 timp-3 subsequ examin effect u0126 invas metastasi orthotop inocul noz cell nude mice direct liver invas cancer cell detect mice control group on mous u0126-treat group most primari tumor u0126-treat group expand liver invad liver vessel invas liver evid mice control group on mous u0126-treat group lymph node metastas periton dissemin recogn mice both group mice u0126-treat group mice vehicl control group metastas lung present result suggest mek inhibitor u0126 prolong surviv mice noz tumor inhibit direct liver invas vessel invas cancer cell via down-regul matrix degrad abil cancer cell
object human selenoprotein hselp uniqu protein contain selenocystein encod infram uga typic function stop codon function hselp remain unclear part due inabl express gene recombin techniqu studi investig express purif recombin hselp prokaryot express system activ induc apoptosi vitro method shorter hselp isoform clone selenocystein seci 40th posit terminu hselp shorter isoform mutat cystein pcr express coli express product purifi deae column identifi western blot subsequ function induct mitochondri apoptot activ studi result mutant hselp shorter isoform express prokaryot system purifi deae column homogen purifi product hselp280m induc open mitochondri permeabl transit pore ptp decreas transmembran potenti dose-depend manner event abolish ptp specif inhibitor conclus hselp280m induc open mitochondri ptp provid basi investig structur function recombin hselp
object investig whether correl exist mrna express igf-ii hepatocyt growth factor hgf tumor progress prognosi gastric cancer method situ hybrid techniqu us examin mrna express igf-ii hgf immunohistochem techniqu us examin protein express cd34 105 specimen gastric carcinoma result situ hybrid reveal posit rate igf-ii mrna hgfmrna 49.5 57.1 respect stage t3-t4 case posit mrna express rate igf-ii hgf frequenc vessel invas lymph node metastasi distant metastasi significantli higher stage t1-t2 case mean microvascular densiti mvd stage t3-t4 tumor vessel invas lymph node metastasi distant metastasi significantli frequent stage t1-t2 tumor mean mvd tumor posit igf-ii hgf express significantli higher tumor igf-ii hgf express posit correl mvd express igf-ii hgf mean surviv time 5-year surviv rate case posit igf-ii hgf express mvd valu 39.5 significantli shorter case neg igf-ii hgf express mvd valu &lt 39.5 conclus igf-ii hgf promot angiogenesi gastric cancer take part tumor invas metastasi us prognost marker gastric cancer clinic practic
object evalu efficaci safeti imatinib mesyl treatment patient preoper supplement us alon unresect metastat gastrointestin stromal tumor gist method total case advanc gist prove patholog among cd117 detect posit patient patient receiv imatinib mesyl befor oper patient unresect metastat gist receiv oral imatinib mesyl daili dose 200-600 three patient lost follow-up object effect evalu patient result fifteen patient 60.0 achiev partial respons 20.0 stabl diseas 20.0 progress diseas median time progress mttp month most experienc benefit twenti-two patient follow-up year 1-year surviv rate 86.4 overal median surviv obtain date twenti-seven patient valuabl toxic assess accord standard main toxic includ grade i-ii edema periorbit area lower limb 85.2 23/27 patient leukopenia present 40.7 11/27 intratumor bleed 7.4 2/27 toxic includ mild fatigu 29.6 abdomin pain 14.8 effloresc 11.1 nausea vomit 18.5 conclus inhibitor tyrosin kinas imatinib mesyl gener well toler prove effect safe prolong treatment patient advanc gastrointestin stromal tumor
hepatocellular carcinoma hcc develop background chronic hepat cirrhosi slow progress diseas facilit identif discret patholog stage increas rate hepatocyt prolifer preneoplast nodul earli event progress hcc increas cell turnov result select monoclon hepatocyt popul subsequ undergo genom alter lead develop hcc heterogen natur genom alter identifi tumor patient hcc imped identif regulatori pathwai disrupt critic tumor initi howev sever regulatori network import liver cell prolifer character us partial hepatectomi model vivo model liver cell cycl progress like relev pathogenesi hepatocellular carcinoma
purpos cell transcript factor nuclear effector wnt signal transduct pathwai plai crucial role embryon malign develop previou studi show increas express level tcf mrna liver cancer present paper antisens tcf rna us explor possibl therapeut effect liver cancer cell interrupt abnorm wnt pathwai method antisens express vector contain conserv sequenc tcf cdna construct transfect human liver cancer cell line smmc-7721 tumorigen potenti determin cellular growth assai tumor growth nude mice result stabl transfect anti-sens tcf smmc-7721 cell significantli reduc tcf express both mrna protein level compar parent mock-transfect cell antisens-mediat suppress tcf inhibit vitro prolifer vivo tumor format abil furthermor apoptosi rate antisens transfect cell significantli higher control indic antisens rna suppress malign growth induct apoptosi conclus studi demonstr critic role wnt signal pathwai neoplast growth liver cancer cell suggest inhibit tcf activ antisens tcf rna potenti gene therapi method liver cancer
